<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rimexolone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00896</strong>&#160; (APRD01220)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00896/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00896/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00896.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00896.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00896.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00896.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00896.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00896">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Vexol</td><td>Alcon incorporated</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/corticosteroids">Corticosteroids</a></li></ul></td></tr><tr><th>CAS number</th><td>49697-38-3</td></tr><tr><th>Weight</th><td>Average: 370.525<br>Monoisotopic: 370.250794954</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>34</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>QTTRZHGPGKRAFB-PAIWTFDUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17?,18?,19+,21?,22+,23+,24-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,13R,14S,15S,17S)-17-hydroxy-2,13,14,15-tetramethyl-14-propanoyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC(=O)[C@@]1(C)[C@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Androgens and Derivatives</td></tr><tr><th>Direct parent</th><td>Androgens and Derivatives</td></tr><tr><th>Alternative parents</th><td>Hydroxysteroids; Ketosteroids; Iridoids and Derivatives; Cyclohexanols; Cyclic Alcohols and Derivatives; Ketones; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>monoterpene; 11-noriridane monoterpene; cyclohexanol; cyclic alcohol; ketone; secondary alcohol; enolate; polyamine; alcohol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the androgens and derivatives. These are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.</td></tr><tr><th>Pharmacodynamics</th><td>Rimexolone is a glucocorticoid corticosteroid for systemic use. Corticosteroids suppress the inflammatory response to a variety of inciting agents of a mechanical, chemical, or immunological nature. They inhibit edema, cellular infiltration, capillary dilatation, fibroblastic proliferation, deposition of collagen and scar formation associated with inflammation.</td></tr><tr><th>Mechanism of action</th><td>Rimexolone is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. By binding to the glucocorticoid receptor, this drug ultimately leads to changes in genetic transcription involving the lipocortins and prostaglandins.</td></tr><tr><th>Absorption</th><td>Systemically absorbed.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Undergoes extensive metabolism. Following intravenous administration of radiolabeled rimexolone in rats, more than 80% of the dose was excreted in the feces as rimexolone and metabolites. Metabolites have been shown to be either less active than rimexolone or inactive in human glucocorticoid receptor binding assays.</p></td></tr><tr><th>Route of elimination</th><td>Following IV administration of radio-labelled rimexolone to rats, greater than 80% of the dose is excreted via the feces as rimexolone and metabolites.</td></tr><tr><th>Half life</th><td>The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9796</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7879</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7261</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.616</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5126</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8022</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8142</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9195</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7631</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9521</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6544</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7217</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9396
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9243
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9906
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1317 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8573
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7387
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Alcon laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.alcon.com">Alcon Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Suspension</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>